According to AnthropicAI on Twitter, the Long-Term Benefit Trust has appointed Vas Narasimhan to Anthropic’s Board of Directors, adding more than two decades of medicine and global health leadership, including his tenure as CEO of Novartis (source: Anthropic on X, April 14, 2026). As reported by Anthropic, this governance move signals deeper focus on safety, responsible deployment, and healthcare-grade reliability for Claude models in regulated sectors. According to Anthropic’s post, Narasimhan’s expertise could accelerate clinical-grade AI evaluation, pharma partnerships, and global market access strategies, creating opportunities for enterprise healthcare AI, clinical decision support, real‑world evidence analytics, and compliance-ready model governance.